Efectividad de las vacunas COVID-19

Katherine Del Pilar Castañeda-Rodriguez, Javier Gamboa-Cruzado, José Niño Montero, Luis Izquierdo Villavicencio, Abel Anderson Zavala-Gutierrez

Resumen


La pandemia del SARS-CoV-2, ha generado que se realicen esfuerzos considerables en el desarrollo de las vacunas, para comprobar su efectividad se requiere que ensayos clínicos y emplearlos en la población a nivel mundial. Se realizó una revisión sistemática de literatura (RSL) del COVID-19 y su impacto en el desarrollo de las vacunas desde el 2019 hasta el 2022. La estrategia de búsqueda consiguió obtener 8 646 artículos, escogidos de las 6 fuentes de investigación (Wiley Online Library, Taylor & Francis, THE LANCET Infectious Diseases, National Library of Medicine, Nature Portfolio y Oxford Academic), luego se realizó un filtrado de 4 etapas con 2 criterios de exclusión cada una de ellas, quedando solo 78 artículos, los cuáles se utilizaron para responder tres preguntas de investigación planteadas. Se identificaron en los artículos científicos analizados, los laboratorios más referenciados que desarrollaron vacunas Pfizer/ BioNTech, Moderna, AstraZeneca, Sinovac, Sinopharm y Sputnik V, se identificó la utilización de nanotecnología en el diseño de las vacunas, principalmente utilizaron ARN mensajero, vector viral y subunidades proteicas, según el caso con coadyuvantes que potencia la inmunogenicidad. Los estudios demostraron buena efectivad, en los diferentes grupos priorizados y gracias a la dosificación de las inmunizaciones contra la COVID-19, se ha prevenido el número de casos graves y por ende la tasa de mortalidad. Sin embargo, se recomienda promoción y educación sanitaria a la población en general para incentivar la aceptación.


Palabras clave


COVID-19, SARS-CoV-2, vacunas, coronavirus, inmunopatología

Texto completo:

PDF

Referencias


Abu Farha, R. K., Alzoubi, K. H., Khabour, O. F., & Alfaqih, M. A. (2021). Exploring perception and hesitancy toward COVID-19 vaccine: A study from Jordan. Human vaccines & immunotherapeutics, 17(8), 2415–2420. https://doi.org/10.1080/21645515.2021.1888633

Ahsan, M. A., Liu, Y., Feng, C., Zhou, Y., Ma, G., Bai, Y., & Chen, M. (2021). Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2. Briefings in bioinformatics, 22(2), 714–725. https://doi.org/10.1093/bib/bbaa416

Akarsu, B., Canbay Özdemir, D., Ayhan Baser, D., Aksoy, H., Fidancı, İ., & Cankurtaran, M. (2021). While studies on COVID-19 vaccine is ongoing, the public's thoughts and attitudes to the future COVID-19 vaccine. International journal of clinical practice, 75(4), e13891. https://doi.org/10.1111/ijcp.13891

Al-Metwali, B. Z., Al-Jumaili, A. A., Al-Alag, Z. A., & Sorofman, B. (2021). Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model. Journal of evaluation in clinical practice, 27(5), 1112–1122. https://doi.org/10.1111/jep.13581

Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., Österdahl, M. F., Cheetham, N. J., Drew, D. A., Nguyen, L. H., Pujol, J. C., Hu, C., & Steves, C. J. (2022). Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet. Infectious diseases, 22(1), 43–55. https://doi.org/10.1016/S1473-3099(21)00460-6

Anwar M. M. (2020). Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. Journal of immunoassay & immunochemistry, 41(6), 960–975. https://doi.org/10.1080/15321819.2020.1865400

Arnold, J., Winthrop, K., & Emery, P. (2021). COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford, England), 60(8), 3496–3502. https://doi.org/10.1093/rheumatology/keab223

Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M. C., O'Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020). Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 75(7), 1564–1581. https://doi.org/10.1111/all.14364

Baker, D., Roberts, C., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020). COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clinical and experimental immunology, 202(2), 149–161. https://doi.org/10.1111/cei.13495

Bignucolo, A., Scarabel, L., Mezzalira, S., Polesel, J., Cecchin, E., & Toffoli, G. (2021). Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines, 9(8), 825. https://doi.org/10.3390/vaccines9080825

Bookstein Peretz, S., Regev, N., Novick, L., Nachshol, M., Goffer, E., Ben-David, A., Asraf, K., Doolman, R., Levin, E. G., Regev Yochay, G., & Yinon, Y. (2021). Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 58(3), 450–456. https://doi.org/10.1002/uog.23729

Boschiero, M. N., Palamim, C., & Marson, F. (2021). The hindrances to perform the COVID-19 vaccination in Brazil. Human vaccines & immunotherapeutics, 17(11), 3989–4004. https://doi.org/10.1080/21645515.2021.1955607

Brillo, E., Tosto, V., Gerli, S., & Buonomo, E. (2021). COVID-19 vaccination in pregnancy and postpartum. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 1–20. Advance online publication. https://doi.org/10.1080/14767058.2021.1920916

Calvo Fernández, E., & Zhu, L. Y. (2021). Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future. British journal of clinical pharmacology, 87(9), 3408–3424. https://doi.org/10.1111/bcp.14686

Carpio, C. E., Sarasty, O., Hudson, D., Macharia, A., & Shibia, M. (2021). The demand for a COVID-19 vaccine in Kenya. Human vaccines & immunotherapeutics, 17(10), 3463–3471. https://doi.org/10.1080/21645515.2021.1938494

Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020). Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS nano, 14(7), 7760–7782. https://doi.org/10.1021/acsnano.0c04006

Chauhan, N., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021). COVID-19: fighting the invisible enemy with microRNAs. Expert review of anti-infective therapy, 19(2), 137–145. https://doi.org/10.1080/14787210.2020.1812385

Chen J. M. (2021). Live unattenuated vaccines for controlling viral diseases, including COVID-19. Journal of medical virology, 93(4), 1943–1949. https://doi.org/10.1002/jmv.26453

Chung, Y. H., Beiss, V., Fiering, S. N., & Steinmetz, N. F. (2020). COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS nano, 14(10), 12522–12537. https://doi.org/10.1021/acsnano.0c07197

Cooper, S., van Rooyen, H., & Wiysonge, C. S. (2021). COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?. Expert review of vaccines, 20(8), 921–933. https://doi.org/10.1080/14760584.2021.1949291

Dinleyici, E. C., Borrow, R., Safadi, M., van Damme, P., & Munoz, F. M. (2021). Vaccines and routine immunization strategies during the COVID-19 pandemic. Human vaccines & immunotherapeutics, 17(2), 400–407. https://doi.org/10.1080/21645515.2020.1804776

Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020). A systematic review of SARS-CoV-2 vaccine candidates. Signal transduction and targeted therapy, 5(1), 237. https://doi.org/10.1038/s41392-020-00352-y

Ella, R., Reddy, S., Jogdand, H., Sarangi, V., Ganneru, B., Prasad, S., Das, D., Raju, D., Praturi, U., Sapkal, G., Yadav, P., Reddy, P., Verma, S., Singh, C., Redkar, S. V., Gillurkar, C. S., Kushwaha, J. S., Mohapatra, S., Bhate, A., Rai, S., Panda, S., Abraham, P., Gupta, N., Ella, K., Bhargava, B., & Vadrevu, K. M. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet. Infectious diseases, 21(7), 950–961. https://doi.org/10.1016/S1473-3099(21)00070-0

Espejo, A. P., Akgun, Y., Al Mana, A. F., Tjendra, Y., Millan, N. C., Gomez-Fernandez, C., & Cray, C. (2020). Review of Current Advances in Serologic Testing for COVID-19. American journal of clinical pathology, 154(3), 293–304. https://doi.org/10.1093/ajcp/aqaa112

Fang, B., & Meng, Q. H. (2020). The laboratory's role in combating COVID-19. Critical reviews in clinical laboratory sciences, 57(6), 400–414. https://doi.org/10.1080/10408363.2020.1776675

Filtenborg, L., Zhang, Y., Foged, C., & Thakur, A. (2020). The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in immunology, 11, 1817. https://doi.org/10.3389/fimmu.2020.01817

Goncu Ayhan, S., Oluklu, D., Atalay, A., Menekse Beser, D., Tanacan, A., Moraloglu Tekin, O., & Sahin, D. (2021). COVID-19 vaccine acceptance in pregnant women. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 154(2), 291–296. https://doi.org/10.1002/ijgo.13713

Grigoryan, L., & Pulendran, B. (2020). The immunology of SARS-CoV-2 infections and vaccines. Seminars in immunology, 50, 101422. https://doi.org/10.1016/j.smim.2020.101422

Gursoy, D. Can, A. S., Williams, N., & Ekinci, Y. (2021) Evolving impacts of COVID-19 vaccination intentions on travel intentions, The Service Industries Journal, 41(11-12), 719-733 https://doi.org/10.1080/02642069.2021.1938555

Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L., Shu, Q., Wu, Z., Zhao, Y., Li, Q., & Gao, Q. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(12), 1645–1653. https://doi.org/10.1016/S1473-3099(21)00319-4

Heinz, F. X., & Stiasny, K. (2021). Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ vaccines, 6(1), 104. https://doi.org/10.1038/s41541-021-00369-6

Henry, D. A., Jones, M. A., Stehlik, P., & Glasziou, P. P. (2021). Effectiveness of COVID-19 vaccines: findings from real world studies. The Medical journal of Australia, 215(4), 149–151.e1. https://doi.org/10.5694/mja2.51182

Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K., & Pollard, A. J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet. Infectious diseases, 21(2), e26–e35. https://doi.org/10.1016/S1473-3099(20)30773-8

İkiışık, H., Akif Sezerol, M., Taşçı, Y., & Maral, I. (2021). COVID-19 vaccine hesitancy: A community-based research in Turkey. International journal of clinical practice, 75(8), e14336. https://doi.org/10.1111/ijcp.14336

Jentsch, P. C., Anand, M., & Bauch, C. T. (2021). Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. The Lancet. Infectious diseases, 21(8), 1097–1106. https://doi.org/10.1016/S1473-3099(21)00057-8

Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020). Immunological considerations for COVID-19 vaccine strategies. Nature reviews. Immunology, 20(10), 615–632. https://doi.org/10.1038/s41577-020-00434-6

Kaur, S. P., & Gupta, V. (2020). COVID-19 Vaccine: A comprehensive status report. Virus research, 288, 198114. https://doi.org/10.1016/j.virusres.2020.198114

Kerboua K. E. (2020). The perplexing question of trained immunity vs adaptive memory in COVID-19. Journal of medical virology, 92(10), 1858–1863. https://doi.org/10.1002/jmv.26083

Kilic, M., Ustundag Ocal, N., & Uslukilic, G. (2021). The relationship of Covid-19 vaccine attitude with life satisfaction, religious attitude and Covid-19 avoidance in Turkey. Human vaccines & immunotherapeutics, 17(10), 3384–3393. https://doi.org/10.1080/21645515.2021.1938493

Kitchenham, B., Pretorius, R., Budgen, D., Pearl Brereton, O., Turner, M., Niazi, M., & Linkman, S. (2010). Systematic literature reviews in software engineering-A tertiary study. Information and Software Technology, 52(8), 792–805. https://doi.org/10.1016/j.infsof.2010.03.006

Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(1), 1-12. https://www.nature.com/articles/s41586-020-2798-3

Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O.(2021). Estrategias de vacunas contra el SARS-CoV-2: una revisión exhaustiva de los candidatos de la fase 3. Vacunas npj 6 , 28 https://doi.org/10.1038/s41541-021-00292-w

Lai, C. C., Chen, I. T., Chao, C. M., Lee, P. I., Ko, W. C., & Hsueh, P. R. (2021). COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert review of vaccines, 20(8), 1013–1025. https://doi.org/10.1080/14760584.2021.1949293

Mohapatra, R. K., Pintilie, L., Kandi, V., Sarangi, A. K., Das, D., Sahu, R., & Perekhoda, L. (2020). The recent challenges of highly contagious COVID-19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy. Chemical biology & drug design, 96(5), 1187–1208. https://doi.org/10.1111/cbdd.13761

Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021). Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. The Lancet. Infectious diseases, 21(6), 793–802. https://doi.org/10.1016/S1473-3099(21)00143-2

Mouliou, D. S., & Gourgoulianis, K. I. (2021). False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert review of respiratory medicine, 15(8), 993–1002. https://doi.org/10.1080/17476348.2021.1917389

Nhamo, G. (2021). COVID-19 Vaccines Development Discord: A Focus on the BRICS and Implications for Africa’s Access and Affordability Matters. Politikon, 1(1), 1-20. https://doi.org/10.1080/02589346.2021.1913797

Noh, E. B., Nam, H. K., & Lee, H. (2021). Which Group Should be Vaccinated First?: A Systematic Review. Infection & chemotherapy, 53(2), 261–270. https://doi.org/10.3947/ic.2021.0029

Novak, N., Peng, W., Naegeli, M. C., Galvan, C., Kolm-Djamei, I., Brüggen, C., Cabanillas, B., Schmid-Grendelmeier, P., & Catala, A. (2021). SARS-CoV-2, COVID-19, skin and immunology - What do we know so far?. Allergy, 76(3), 698–713. https://doi.org/10.1111/all.14498

Park, K. S., Sun, X., Aikins, M. E., & Moon, J. J. (2021). Non-viral COVID-19 vaccine delivery systems. Advanced drug delivery reviews, 169, 137–151. https://doi.org/10.1016/j.addr.2020.12.008

Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020). SARS-CoV-2 Vaccine Development: Current Status. Mayo Clinic proceedings, 95(10), 2172–2188. https://doi.org/10.1016/j.mayocp.2020.07.021

Rapaka, R. R., Hammershaimb, E. A., & Neuzil, K. M. (2022). Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(2), 352–358. https://doi.org/10.1093/cid/ciab213

Raus, K., Mortier, E., & Eeckloo, K. (2021). Ethical reflections on Covid-19 vaccines, Acta Clinica Belgica, 77(3), 600-605. https://doi.org/10.1080/17843286.2021.1925027

Regehr, C., & Goel, V. (2020). Managing COVID-19 in a large urban research-intensive university. Journal of Loss and Trauma, 25(6-7), 523-539. https://doi.org/10.1080/15325024.2020.1771846

Robinson, E., Jones, A., Lesser, I., & Daly, M. (2021). International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples. Vaccine, 39(15), 2024–2034. https://doi.org/10.1016/j.vaccine.2021.02.005

Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021). Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature reviews. Immunology, 21(8), 475–484. https://doi.org/10.1038/s41577-021-00578-z

Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M., Rabin, R., Vieths, S., Agache, I., Akdis, M., Barber, D., Breiteneder, H., Chinthrajah, S., Chivato, T., Collins, W., Eiwegger, T., Fast, K., Fokkens, W., O'Hehir, R. E., Ollert, M., & Nadeau, K. C. (2021). Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy, 76(6), 1640–1660. https://doi.org/10.1111/all.14840

Sauré, D., O'Ryan, M., Torres, J. P., Zuniga, M., Santelices, E., & Basso, L. J. (2022). Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. The Lancet. Infectious diseases, 22(1), 56–63. https://doi.org/10.1016/S1473-3099(21)00479-5

Schijns, V., & Lavelle, E. C. (2020). Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. European journal of immunology, 50(7), 932–938. https://doi.org/10.1002/eji.202048693

Sherman, S. M., Smith, L. E., Sim, J., Amlôt, R., Cutts, M., Dasch, H., Rubin, G. J., & Sevdalis, N. (2021). COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. Human vaccines & immunotherapeutics, 17(6), 1612–1621. https://doi.org/10.1080/21645515.2020.1846397

Shin, M. D., Shukla, S., & Chung, Y. H. (2020). Desarrollo de la vacuna COVID-19 y un posible camino a seguir con nanomateriales. Nat. Nanotecnología. 15, 646–655. https://doi.org/10.1038/s41565-020-0737-y

Shrotri, M., Krutikov, M., Palmer, T., Giddings, R., Azmi, B., Subbarao, S., Fuller, C., Irwin-Singer, A., Davies, D., Tut, G., Lopez Bernal, J., Moss, P., Hayward, A., Copas, A., & Shallcross, L. (2021). Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. The Lancet. Infectious diseases, 21(11), 1529–1538. https://doi.org/10.1016/S1473-3099(21)00289-9

Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and ageing, 50(2), 279–283. https://doi.org/10.1093/ageing/afaa274

Soleimanpour, S., & Yaghoubi, A. (2021). COVID-19 vaccine: where are we now and where should we go?. Expert review of vaccines, 20(1), 23–44. https://doi.org/10.1080/14760584.2021.1875824

Stratford, J., MacKenzie, E., & Mockford, E. (2020). Balancing speed and safety: the Authorisation of Covid-19 vaccines and medicines. Judicial Review, 25(2), 105-117. https://doi.org/10.1080/10854681.2020.1780664

Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N. M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020). Vaccines for COVID-19. Clinical and experimental immunology, 202(2), 162–192. https://doi.org/10.1111/cei.13517

Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021). Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature reviews. Immunology, 21(10), 626–636. https://doi.org/10.1038/s41577-021-00592-1

Verdecia, M., Kokai-Kun, J. F., Kibbey, M., Acharya, S., Venema, J., & Atouf, F. (2021). COVID-19 vaccine platforms: Delivering on a promise?. Human vaccines & immunotherapeutics, 17(9), 2873–2893. https://doi.org/10.1080/21645515.2021.1911204

Wake A. D. (2021). The Willingness to Receive COVID-19 Vaccine and Its Associated Factors: "Vaccination Refusal Could Prolong the War of This Pandemic" - A Systematic Review. Risk management and healthcare policy, 14, 2609–2623. https://doi.org/10.2147/RMHP.S311074

Wan, E., Chui, C., Lai, F., Chan, E., Li, X., Yan, V., Gao, L., Yu, Q., Lam, I., Chun, R., Cowling, B. J., Fong, W. C., Lau, A., Mok, V., Chan, F., Lee, C. K., Chan, L., Lo, D., Lau, K. K., Hung, I., … Wong, I. (2022). Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. The Lancet. Infectious diseases, 22(1), 64–72. https://doi.org/10.1016/S1473-3099(21)00451-5

Wang, Y., Wang, L., Cao, H., & Liu, C. (2021). SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. Journal of medical virology, 93(2), 892–898. https://doi.org/10.1002/jmv.26320

Wibawa T. (2021). COVID-19 vaccine research and development: ethical issues. Tropical medicine & international health, TM & IH, 26(1), 14–19. https://doi.org/10.1111/tmi.13503

Wu, S., Huang, J., Zhang, Z., Wu, J., Zhang, J., Hu, H., Zhu, T., Zhang, J., Luo, L., Fan, P., Wang, B., Chen, C., Chen, Y., Song, X., Wang, Y., Si, W., Sun, T., Wang, X., Hou, L., & Chen, W. (2021a). Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. The Lancet. Infectious diseases, 21(12), 1654–1664. https://doi.org/10.1016/S1473-3099(21)00396-0

Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., Wang, L., Zhao, G., Ding, Y., Zhao, Y., & Yin, W. (2021b). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(6), 803–812. https://doi.org/10.1016/S1473-3099(20)30987-7

Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., Huang, W., Xu, W., Huang, B., Wang, H., Wang, W., Zhang, W., Li, N., Xie, Z., Ding, L., You, W., & Yang, X. (2021). Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet. Infectious diseases, 21(1), 39–51. https://doi.org/10.1016/S1473-3099(20)30831-8

Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K. (2020). Recombinant vaccines for COVID-19. Human vaccines & immunotherapeutics, 16(12), 2905–2912. https://doi.org/10.1080/21645515.2020.1820808

Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C., Fang, X., Wang, C., Zhao, X., Huang, E., Wu, C., Zhong, Z., Wang, F., Duan, X., Tian, S., Wu, L., Liu, Y., Luo, Y., Chen, Z., Li, F., & Gao, G. F. (2021). Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet. Infectious diseases, 21(8), 1107–1119. https://doi.org/10.1016/S1473-3099(21)00127-4

Yılmaz, M., & Sahin, M. K. (2021). Parents' willingness and attitudes concerning the COVID-19 vaccine: A cross-sectional study. International journal of clinical practice, 75(9), e14364. https://doi.org/10.1111/ijcp.14364

Young Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021). COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced drug delivery reviews, 170, 1–25. https://doi.org/10.1016/j.addr.2020.12.011

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4

Zheng, Y., Li, R., & Liu, S. (2020). Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines. Journal of medical virology, 92(9), 1495–1500. https://doi.org/10.1002/jmv.26009

Zhou, W., & Wang, W. (2021). Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal transduction and targeted therapy, 6(1), 226. https://doi.org/10.1038/s41392-021-00644-x


Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Copyright (c) 2022 Boletín de Malariología y Salud Ambiental